Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Improving outcomes for patients with diffuse large B-cell lymphoma Flowers CR; Sinha R; Vose JMCA Cancer J Clin 2010[Nov]; 60 (6): 393-408Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring form of non-Hodgkin lymphoma in the western world. Until the mid 1990s the incidence of DLBCL increased in both sexes, across racial categories, and across all age groups except the very young, the etiology of most cases remains unknown. DLBCL is associated with an aggressive natural history, but it can be cured with combination chemotherapy regimens like cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), which has been the mainstay of therapy for several decades. Remarkable progress has been made in understanding the biological heterogeneity of DLBCL and in improving survival for DLBCL patients with novel combinations of chemotherapy and immunotherapy. Gene expression profiling (GEP) has uncovered DLBCL subtypes that have distinct clinical behaviors and prognoses, and the addition of the monoclonal antibody, rituximab, to CHOP has markedly improved outcomes. Future approaches to DLBCL management will use molecular signatures identified through GEP to provide prognostic information and to isolate therapeutic targets that are being evaluated for DLBCL patients who relapse or those with high risk disease.|Antibodies, Monoclonal, Murine-Derived/administration & dosage[MESH]|Antineoplastic Combined Chemotherapy Protocols/*therapeutic use[MESH]|Biomarkers, Tumor/genetics[MESH]|Clinical Trials as Topic[MESH]|Cyclophosphamide/administration & dosage[MESH]|Doxorubicin/administration & dosage[MESH]|Evidence-Based Medicine[MESH]|Humans[MESH]|Incidence[MESH]|Lymphoma, Large B-Cell, Diffuse/*diagnosis/*drug therapy/epidemiology/genetics[MESH]|Prednisone/administration & dosage[MESH]|Prognosis[MESH]|Risk Factors[MESH]|Rituximab[MESH]|Treatment Outcome[MESH]|United States/epidemiology[MESH]|Vincristine/administration & dosage[MESH] |
